<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057468</url>
  </required_header>
  <id_info>
    <org_study_id>17300534</org_study_id>
    <nct_id>NCT05057468</nct_id>
  </id_info>
  <brief_title>Second-line Treatment of Primary Autoimmune Hemolytic Anemia</brief_title>
  <official_title>Cyclosporine as a Second-line Treatment of Primary Autoimmune Hemolytic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous&#xD;
      case reports and retrospective data. This study compares cyclosporin versus rituximab in&#xD;
      steroid-refractory anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Auto-immune hemolytic anemia (AIHA) is a heterogeneous syndrome in adults. This disease is&#xD;
      associated with significant morbidity-mortality. First-line treatment with prolonged&#xD;
      corticosteroid is well identified but there is not enough data about cyclosporine treatment&#xD;
      in case of resistance or dependence on steroids.&#xD;
&#xD;
      the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous&#xD;
      case reports and retrospective data. This drug is cheap, licensed in immunologic diseases,&#xD;
      and does not expose to major infections. So, we compare cyclosporin versus rituximab in&#xD;
      steroid-refractory anemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of complete response</measure>
    <time_frame>3months</time_frame>
    <description>Hb ≥12 g/dL and normalization of all hemolytic markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the proportion of partial response</measure>
    <time_frame>3months</time_frame>
    <description>(Hb ≥10 g/dL or at least 2 g/dL increase in Hb, and no transfusion requirement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of adverse events</measure>
    <time_frame>3months</time_frame>
    <description>according to Common Terminology Criteria for Adverse Events Version 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Autoimmune Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5-5mg/kg of cyclosporine daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>375 mg/ m2 weekly dose for a maximum of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>2.5-5 mg orally for 3 months</description>
    <arm_group_label>Cyclosporine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/ m2 weekly dose for a maximum of 4 weeks</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged more than 18 years old from any sex with a diagnosis of primary warm&#xD;
             autoimmune hemolytic anemia (AIHA) based on the presence of hemolytic anemia and&#xD;
             serological evidence of anti-erythrocyte antibodies, detectable by the direct&#xD;
             antiglobulin test who have disease progression or failure after treatment with steroid&#xD;
             therapy, or who are intolerant to treatment, or who refuse standard treatment.&#xD;
&#xD;
          -  No evidence of a lymphoproliferative malignancy or other autoimmune-related underlying&#xD;
             conditions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any contraindications to the drugs of the study.&#xD;
&#xD;
          -  any identified secondary cause of the AIHA.&#xD;
&#xD;
          -  pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ghada Abdallah</last_name>
    <phone>+201008138002</phone>
    <email>ghadaelsayed2008@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut,</city>
        <state>Assiut</state>
        <zip>17111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai Kamal, MD</last_name>
      <phone>+201223971678</phone>
      <email>mai_heamatology@aun.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ghada E. M. Abdallah</investigator_full_name>
    <investigator_title>lecturer in internal medicine department of faculty of medicine,Assiut university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

